{"schema_version":"1.0","type":"article","title":"中風新藥先在中國上市，拜耳只剩一年領先","url":"https://drugnews.com.tw/articles/2026-11-12-bayer-sunharbo-asundexian-stroke-factor-xi-china-first-milvexian.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-12-bayer-sunharbo-asundexian-stroke-factor-xi-china-first-milvexian.md","lang":"zh-Hant","date":"2026-11-12","publish_at":"2026-11-12T08:00:00+08:00","updated_at":"2026-11-12","category":"製藥巨頭系列","topic":"製藥巨頭系列","tags":["中風","拜耳","Factor XI","抗凝血","必治妥"],"summary":"FDA 11 月 9 日核准拜耳 Sunharbo，首個 Factor XIa 抑制劑；中國 10 月 26 日先批。三期試驗再中風降 26%、大出血無顯著增加，美國月價 748.5 美元。必治妥與嬌生的 milvexian 中風數據年底前公布。","key_points":["FDA 於 2026 年 11 月 9 日核准拜耳 Sunharbo（asundexian）用於非心因性中風與高風險 TIA 後的二級預防，中國藥監局 10 月 26 日已先核准。","OCEANIC-STROKE 收 12,327 人，缺血性中風 6.2% 對 8.4%，ISTH 大出血 1.9% 對 1.7% 無顯著差異；75 歲以上與高風險 TIA 分組出血較多。","必治妥在 10 月 29 日法說會表示 milvexian 中風三期數據在 2026 年底前公布，心房顫動試驗在 2027 年第一季。"],"facts":[{"claim":"FDA 核准 Sunharbo（asundexian）用於非心因性缺血性中風或高風險 TIA 後降低中風風險","value":"2026-11-09","unit":"date","as_of":"2026-11-09","source":"BioPharma Dive 2026-11-09"},{"claim":"中國藥監局核准 Sunharbo，全球首個獲准 Factor XIa 抑制劑","value":"2026-10-26","unit":"date","as_of":"2026-10-26","source":"Bayer 2026-10-26"},{"claim":"OCEANIC-STROKE 隨機分派人數","value":12327,"unit":"人","as_of":"2026-11-09","source":"NeurologyLive 2026-11-09"},{"claim":"缺血性中風發生率 Sunharbo 對安慰劑","value":"6.2 vs 8.4","unit":"%","as_of":"2026-11-09","source":"NeurologyLive 2026-11-09"},{"claim":"缺血性中風相對風險降幅","value":26,"unit":"%","as_of":"2026-11-09","source":"NeurologyLive 2026-11-09"},{"claim":"ISTH 大出血 Sunharbo 對安慰劑","value":"1.9 vs 1.7","unit":"%","as_of":"2026-11-09","source":"NeurologyLive 2026-11-09"},{"claim":"75 歲以上 ISTH 大出血","value":"2.6 vs 1.7","unit":"每 100 人年","as_of":"2026-11-09","source":"Bayer／StockTitan 2026-11-09"},{"claim":"高風險 TIA 分組 ISTH 大出血","value":"2.9 vs 1.0","unit":"每 100 人年","as_of":"2026-11-09","source":"Bayer／StockTitan 2026-11-09"},{"claim":"失能性中風風險比","value":"0.69","unit":"HR","as_of":"2026-11-07","source":"Tech Times 2026-11-07"},{"claim":"中位治療期間","value":14.2,"unit":"月","as_of":"2026-11-09","source":"NeurologyLive 2026-11-09"},{"claim":"一年需治療人數（NNT）","value":53,"unit":"人","as_of":"2026-11-09","source":"STAT 2026-11-09"},{"claim":"Sunharbo 美國 30 天份標價","value":748.5,"unit":"美元","as_of":"2026-11-09","source":"BioPharma Dive 2026-11-09"},{"claim":"Xarelto 2026 上半年銷售","value":7.38,"unit":"億歐元（年減 43%）","as_of":"2026-11-09","source":"BioPharma Dive 2026-11-09"},{"claim":"Xarelto 2026 第三季銷售年減","value":31,"unit":"%","as_of":"2026-11-03","source":"Yahoo Finance 2026-11-03"},{"claim":"Nubeqa 2026 第三季銷售年增","value":58,"unit":"%","as_of":"2026-11-03","source":"Yahoo Finance 2026-11-03"},{"claim":"LIBREXIA ACS 主要終點 milvexian 對安慰劑","value":"5.4 vs 5.1","unit":"%","as_of":"2026-08-29","source":"ESC 2026-08-29"},{"claim":"LIBREXIA ACS 人數","value":14194,"unit":"人","as_of":"2026-08-29","source":"ESC 2026-08-29"},{"claim":"milvexian 中風二級預防三期數據公布時程","value":"2026 年底前","unit":"時程","as_of":"2026-10-29","source":"Motley Fool 2026-10-29"},{"claim":"milvexian 心房顫動三期數據時程","value":"2027 年第一季","unit":"時程","as_of":"2026-10-29","source":"Motley Fool 2026-10-29"},{"claim":"Leerink 估 milvexian 2032 年風險調整後銷售","value":25,"unit":"億美元","as_of":"2026-11-09","source":"BioPharma Dive 2026-11-09"},{"claim":"諾華收購 Anthos 預付款","value":9.25,"unit":"億美元","as_of":"2025-02-11","source":"Novartis 2025-02-11"},{"claim":"CHANCE 雙抗血小板 90 天再中風率 對 阿斯匹靈","value":"8.2 vs 11.7","unit":"%","as_of":"2013-07-04","source":"NEJM 2013-07-04"},{"claim":"中國缺血性中風盛行人數（2021）","value":2000,"unit":"萬人以上","as_of":"2026-10-26","source":"Bayer 2026-10-26"},{"claim":"腦血管疾病台灣十大死因排名","value":4,"unit":"名","as_of":"2026-10-28","source":"國民健康署 2026-10-28"}],"sections":["01｜第一張藥證給中國，算過病人數就不奇怪","02｜26% 不是最大的降幅，賣點是沒有多流血","03｜同一顆藥在心房顫動慘輸，畫出 Factor XI 的邊界","04｜生意怎麼變：從一天幾塊錢的老藥，到一個月 748.5 美元","05｜必治妥年底交卷，一年領先值多少","06｜台灣病人等的是健保，不是只等藥證","參考資料"],"references":[{"title":"Bayer's SUNHARBO (asundexian) 50 mg tablets, the first and only Factor XIa inhibitor approved in the U.S.","source":"Bayer／StockTitan","date":"2026-11-09","url":"https://www.stocktitan.net/news/BAYRY/bayer-s-sunharbo-asundexian-50-mg-tablets-the-first-and-only-factor-onpa40n72aki.html"},{"title":"Asundexian first Factor XIa inhibitor approved in China for stroke risk reduction after priority review","source":"Bayer","date":"2026-10-26","url":"https://www.bayer.com/media/en-us/asundexian-first-factor-xia-inhibitor-approved-in-china-for-stroke-risk-reduction-after-priority-review/"},{"title":"FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention","source":"NeurologyLive","date":"2026-11-09","url":"https://www.neurologylive.com/view/fda-approves-asundexian-treatment-secondary-stroke-prevention"},{"title":"Bayer's novel drug for stroke recurrence wins FDA approval","source":"STAT","date":"2026-11-09","url":"https://statnews.com/2026/11/09/cardiovascular-stroke-recurrence-bayer-drug-fda-approval"},{"title":"Bayer wins FDA nod for a new kind of blood thinner","source":"BioPharma Dive","date":"2026-11-09","url":"https://www.biopharmadive.com/news/bayer-sunharbo-asundexian-fda-approve-stroke-factor-xi/872837/"},{"title":"Bayer's Asundexian Cuts Recurrent Stroke Risk by 26% Without Added Bleeding, Wins China Approval","source":"Tech Times","date":"2026-11-07","url":"https://www.techtimes.com/articles/330236/20261107/bayers-asundexian-cuts-recurrent-stroke-risk-26-without-added-bleeding-wins-china-approval-fda.htm"},{"title":"Bayer AG (BAYRY) Q3 2026 Earnings Call Highlights","source":"Yahoo Finance","date":"2026-11-03","url":"https://finance.yahoo.com/healthcare/articles/bayer-ag-bayry-q3-2026-210537813.html"},{"title":"Bayer Hesitates to Raise Sales Forecast Despite Asundexian Breakthrough","source":"MarketScreener／Reuters","date":"2026-02-06","url":"https://www.marketscreener.com/news/bayer-hesitates-to-raise-sales-forecast-despite-asundexian-breakthrough-ce7e5ad9dc8ef122"},{"title":"Bristol-Myers Squibb (BMY) Q3 2026 Earnings Call Transcript","source":"The Motley Fool","date":"2026-10-29","url":"https://www.fool.com/earnings/call-transcripts/2026/10/29/bristol-myers-squibb-bmy-q3-2026-earnings-call-transcript/"},{"title":"Milvexian did not reduce cardiovascular events in the LIBREXIA ACS trial","source":"ESC","date":"2026-08-29","url":"https://www.escardio.org/news/press/press-releases/milvexian-did-not-reduce-cardiovascular-events-in-the-librexia-acs-trial/"},{"title":"Update on Phase 3 Librexia ACS Trial","source":"Bristol Myers Squibb","date":"2025-11-13","url":"https://news.bms.com/news/details/2025/Update-on-Phase-3-Librexia-ACS-Trial/default.aspx"},{"title":"Novartis to acquire Anthos Therapeutics for USD 925 million upfront","source":"Novartis","date":"2025-02-11","url":"https://www.novartis.com/news/media-releases/novartis-bolsters-late-stage-cardiovascular-pipeline-agreement-acquire-anthos-therapeutics-usd-925-million-upfront"},{"title":"Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE","source":"New England Journal of Medicine","date":"2013-07-04","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1215340"},{"title":"腦中風防治宣導","source":"衛生福利部國民健康署","date":"2026-10-28","url":"https://mohw.gov.tw/cp-16-88307-1.html"}],"images":[{"alt":"圖1｜Factor XI 藥物的關鍵時間點","url":"https://drugnews.com.tw/assets/articles/bayer-sunharbo-asundexian-stroke-factor-xi-china-first-milvexian/figure-01.png"},{"alt":"圖2｜OCEANIC-STROKE 主要結果","url":"https://drugnews.com.tw/assets/articles/bayer-sunharbo-asundexian-stroke-factor-xi-china-first-milvexian/figure-02.png"},{"alt":"圖3｜Factor XIa 與 Factor Xa 擋在凝血的不同位置","url":"https://drugnews.com.tw/assets/articles/bayer-sunharbo-asundexian-stroke-factor-xi-china-first-milvexian/figure-03.png"},{"alt":"圖4｜三個 Factor XI 藥物的位置","url":"https://drugnews.com.tw/assets/articles/bayer-sunharbo-asundexian-stroke-factor-xi-china-first-milvexian/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/bayer-sunharbo-asundexian-stroke-factor-xi-china-first-milvexian/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-12）。中風新藥先在中國上市，拜耳只剩一年領先。https://drugnews.com.tw/articles/2026-11-12-bayer-sunharbo-asundexian-stroke-factor-xi-china-first-milvexian.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"「FDA 於 2026 年 11 月 9 日核准拜耳 Sunharbo（asundexian）用於非心因性中風與高風險 TIA 後的二級預防」有哪些關鍵變化？","a":"FDA 於 2026 年 11 月 9 日核准拜耳 Sunharbo（asundexian）用於非心因性中風與高風險 TIA 後的二級預防，中國藥監局 10 月 26 日已先核准。"},{"q":"「OCEANIC-STROKE 收 12,327 人，缺血性中風 6.2% 對 8.4%，ISTH 大出血 1.9% 對 1.7% 無顯著差異」有哪些關鍵變化？","a":"OCEANIC-STROKE 收 12,327 人，缺血性中風 6.2% 對 8.4%，ISTH 大出血 1.9% 對 1.7% 無顯著差異；75 歲以上與高風險 TIA 分組出血較多。"},{"q":"「必治妥在 10 月 29 日法說會表示 milvexian 中風三期數據在 2026 年底前公布，心房顫動試驗在 2027 年第一季」有哪些關鍵變化？","a":"必治妥在 10 月 29 日法說會表示 milvexian 中風三期數據在 2026 年底前公布，心房顫動試驗在 2027 年第一季。"}]}